Combined use of PRAME inhibitors and HDAC inhibitors

Details for Australian Patent Application No. 2005210106 (hide)

Owner Topotarget UK Limited

Inventors Bernards, Rene; Wang, Liming; Epping, Mirjam

Agent Davies Collison Cave

Pub. Number AU-B-2005210106

PCT Pub. Number WO2005/074995

Priority 0401876.8 28.01.04 GB

Filing date 27 January 2005

Wipo publication date 18 August 2005

Acceptance publication date 29 July 2010

International Classifications

A61K 31/16 (2006.01) - Amides, e.g. hydroxamic acids

A61K 31/203 (2006.01)

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

Event Publications

17 August 2006 PCT application entered the National Phase

  PCT publication WO2005/074995 Priority application(s): WO2005/074995

22 July 2010 Assignment before Grant

  Vereniging Het Nederlands Kanker Instituut The application has been assigned to Topotarget UK Limited

29 July 2010 Application Accepted

  Published as AU-B-2005210106

25 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005210114-1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors

2005210105-Method of inducing or modulating immune response